On Invalid Date, Phaxiam Therapeutics Sa (NASDAQ: PHXM) reported Q2 2023 earnings per share (EPS) of N/A, up N/A year over year. Total Phaxiam Therapeutics Sa earnings for the quarter were N/A. In the same quarter last year, Phaxiam Therapeutics Sa's earnings per share (EPS) was N/A.
As of Q4 2023, Phaxiam Therapeutics Sa's earnings has grown year over year. Phaxiam Therapeutics Sa's earnings in the past year totalled -$12.13 million.
What was PHXM's revenue last quarter?
On Invalid Date, Phaxiam Therapeutics Sa (NASDAQ: PHXM) reported Q2 2023 revenue of N/A up N/A year over year. In the same quarter last year, Phaxiam Therapeutics Sa's revenue was N/A.
What was PHXM's revenue growth in the past year?
As of Q4 2023, Phaxiam Therapeutics Sa's revenue has grown -77.09% year over year. This is 186.88 percentage points lower than the US Biotechnology industry revenue growth rate of 109.79%. Phaxiam Therapeutics Sa's revenue in the past year totalled $6.35 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.